RECRUITINGOBSERVATIONAL
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
About This Trial
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
Who May Be Eligible (Plain English)
Who May Qualify:
- Currently using one or more topical glaucoma antihypertensives
- Self-described symptoms of ocular surface discomfort
- Xiidra is being prescribed as part of the subject's standard care
Who Should NOT Join This Trial:
- History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
- current use of topical cyclosporine
- current use of topical steroids
- incisional ocular surgery within 6 months
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Currently using one or more topical glaucoma antihypertensives
* Self-described symptoms of ocular surface discomfort
* Xiidra is being prescribed as part of the subject's standard care
Exclusion Criteria:
* History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
* current use of topical cyclosporine
* current use of topical steroids
* incisional ocular surgery within 6 months
Treatments Being Tested
DRUG
Xiidra (Lifitegrast ophthalmic solution) 5%
FDA approved lifitegrast opthalmic solution eye drop
Locations (1)
Doheny Eye Center UCLA
Fountain Valley, California, United States